von Hippel-Lindau disease is a rare genetic condition. It causes abnormal blood vessel growth, leading to tumors in different parts of the body. These tumors can affect the eyes, brain, spine, adrenal glands, pancreas, and kidneys. People with this disease often have high blood pressure and other symptoms.
Every report comes from a Lived member, sent anonymously.
Have you had Nephrectomy for von Hippel-Lindau Disease?
Von Hippel-Lindau disease (VHL) is a rare inherited condition that causes tumors and fluid-filled cysts to grow in several parts of the body over a person's lifetime. The most common sites are the brain and spinal cord, the retina (the light-sensing layer at the back of the eye), the kidneys, the pancreas and the adrenal glands, which sit on top of the kidneys. Some people also develop tumors of the inner ear or cysts in the reproductive organs. Many VHL tumors are benign, meaning they are not cancer, but they can still cause serious problems because of where they grow. The most typical is a hemangioblastoma, a tumor made of tangled blood vessels that can press on the brain, spinal cord or retina as it enlarges. Kidney tumors and some pancreatic tumors can become cancerous, and kidney cancer is the most common cause of death in VHL. Because growths appear at different ages and many cause no symptoms at first, VHL care centers on regular checkups that find problems early.
VHL is caused by a change (variant) in the VHL gene. This gene normally acts as a brake on cell growth: it helps cells respond correctly to oxygen levels and stops them from making new blood vessels they do not need. When the gene stops working in a cell, that brake is lost, which is why VHL tumors tend to be packed with blood vessels. VHL is passed down in an autosomal dominant pattern, meaning one altered copy of the gene from either parent is enough to cause it. Each child of a parent with VHL has a 50% chance of inheriting it. About 80% of people inherit the change from a parent; in roughly 20%, it arises new in that person, with no family history. Nearly everyone who carries the variant shows some sign of VHL by around age 60, but which organs are affected, and when, varies widely, even among relatives with the same gene change. Some specific gene changes carry a higher chance of pheochromocytoma (an adrenal tumor that releases stress hormones), while others carry a higher chance of kidney cancer. Knowing which type runs in a family can shape a person's screening plan. Nothing a person did or failed to do causes VHL.
VHL may be suspected when someone has a typical tumor at a young age, more than one hemangioblastoma, or a VHL-type tumor and a relative with VHL. Doctors use clinical criteria built on those features. With a known family history, one hemangioblastoma or one VHL-related tumor elsewhere, such as in the kidney, pancreas or adrenal gland, can be enough. Without a family history, two hemangioblastomas, or one hemangioblastoma plus another VHL-related tumor, are usually needed. A genetic test on a blood sample confirms the diagnosis in most people by finding the VHL gene change. Once the change is known in a family, relatives can be tested for that exact variant. A negative result can spare a relative years of unnecessary scans, while a positive result means surveillance can begin in childhood, before tumors cause damage. A genetic counselor can help families think through the results and their implications. After diagnosis, a baseline workup looks for growths throughout the body. It usually includes a dilated eye exam, magnetic resonance imaging (MRI) of the brain and spine with contrast dye, imaging of the abdomen, blood or urine tests for metanephrines (breakdown products of adrenal stress hormones, used to detect pheochromocytoma) and a hearing test.
VHL cannot be cured, because the gene change is present throughout the body, but care aims to find each growth early and treat it at the point where treatment prevents more harm than it causes. That plan rests on lifelong surveillance, ideally coordinated by a team experienced with VHL. A widely used international schedule starts eye exams in the first year of life, yearly blood or urine tests for pheochromocytoma from about age 5, brain and spine MRI and hearing tests from about age 11, and abdominal imaging every two years from about age 15. Intervals change once a tumor is found. Not every tumor needs treatment right away. Many hemangioblastomas grow in spurts separated by long quiet periods, so surgery is generally reserved for those causing symptoms or growing in a way that threatens nearby nerves. Stereotactic radiosurgery, a precisely focused form of radiation, is an option for tumors that are hard to reach or too numerous to remove. Retinal tumors are often treated with laser or freezing treatment, because untreated ones can lead to bleeding, retinal detachment and permanent vision loss. Inner ear tumors are usually removed early, since the hearing loss they cause is often permanent. Kidney tumors are typically watched while small and removed when they reach about 3 centimeters or grow, using kidney-sparing surgery that takes out the tumor but keeps healthy tissue. Because many people need several kidney operations over a lifetime, protecting kidney function is a central goal. Pancreatic cysts rarely need treatment; pancreatic neuroendocrine tumors (growths of hormone-producing cells) are watched or removed depending on their size and growth. Pheochromocytomas release adrenaline-like hormones and are removed surgically, sometimes sparing part of the adrenal gland. Before that surgery, or any other operation, a person with a pheochromocytoma needs treatment with an alpha-blocker, a medicine that relaxes blood vessels, to prevent a dangerous spike in blood pressure during the procedure. Belzutifan (Welireg) is a daily pill that blocks HIF-2 alpha, a protein that drives the growth of VHL tumors. It is approved for adults with VHL whose kidney cancer, brain or spinal hemangioblastomas or pancreatic neuroendocrine tumors need treatment but not immediate surgery. In its main trial, kidney tumors shrank substantially in about half of participants, and it may reduce the need for some operations. It does not cure VHL, and it usually lowers the red blood cell count (anemia), which can cause tiredness and is checked with regular blood tests. It can harm a developing baby and can make some hormonal birth control less effective, so a non-hormonal method is needed during treatment.
VHL is lifelong, and most people need treatment for more than one growth over the years. People often already have several tumors when they are first fully evaluated, and new ones continue to appear over time, more often at younger ages. New growths become uncommon after about age 65, and some surveillance can then be scaled back. Daily life between appointments is often ordinary, but the steady schedule of scans, eye exams and lab tests is a real commitment, and waiting for results can be stressful. Psychological support is a recognized part of VHL care, for the person diagnosed and for relatives facing testing. Outlook has improved considerably since organized surveillance became standard, because tumors are now usually found and treated before they cause lasting damage. Some effects can still be permanent, such as vision or hearing loss, nerve damage from a spinal tumor, or reduced kidney function after repeated surgery, which in some people leads to dialysis or a transplant. Men may develop usually harmless cysts near the testicles; when both sides are affected, these can reduce fertility. Planning a pregnancy is worth discussing ahead of time: guidelines recommend a contrast MRI of the brain and spine before conception to check any hemangioblastomas and related cysts, and scans during pregnancy are done without contrast dye.
If a parent, sibling or child has VHL, ask about genetic testing even if you feel well, since early tumors usually cause no symptoms. Someone with a hemangioblastoma at a young age, more than one hemangioblastoma, or a kidney or adrenal tumor alongside a relevant family history should ask whether VHL has been considered. For people with VHL, contact the care team promptly about new or worsening headaches with nausea or vomiting, trouble with balance or walking, new numbness, weakness or pain in the arms or legs, blurred vision or new floaters. Also report hearing loss, ringing in the ears or dizziness, and episodes of pounding headache, racing heartbeat and sweating, since these can point to an ear tumor or a pheochromocytoma that should be checked before the next scheduled visit. Call 911 for a sudden, severe headache or sudden weakness, numbness or loss of control of the arms or legs, which can mean bleeding from a brain or spinal tumor.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with von Hippel-Lindau Disease is like, what's helped you, or ask the community a question.